Emergent Biosolutions Rating Reiterated by Zacks (EBS)
Emergent Biosolutions (NYSE:EBS)‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Friday. They currently have a $24.00 price target on the stock. Zacks‘s target price suggests a potential upside of 5.22% from the stock’s previous close.
Zacks’ analyst wrote, “Emergent BioSolutions’ first quarter 2014 loss of $0.40 per share was wider than the Zacks Consensus Estimate of a loss of $0.34 primarily due to lower-than-expected revenues. Soft BioThrax sales hurt the top line. Higher costs also adversely impacted results. We are encouraged by the company s decision to expand BioThrax’s label. We are positive on Emergent BioSolutions’ acquisition of Cangene as it has significantly expanded the company’s product portfolio/pipeline. We believe that the stock is fairly valued at current levels with limited scope for upside. Consequently, we initiate coverage on the Zacks Ranked #3 (Hold) stock with a Neutral recommendation.”
EBS has been the subject of a number of other recent research reports. Analysts at Summer Street initiated coverage on shares of Emergent Biosolutions in a research note on Thursday, May 15th. They set a “buy” rating and a $35.00 price target on the stock. Analysts at TheStreet downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, May 12th.
Emergent Biosolutions (NYSE:EBS) traded down 0.57% during mid-day trading on Friday, hitting $22.81. 142,396 shares of the company’s stock traded hands. Emergent Biosolutions has a 52 week low of $16.95 and a 52 week high of $28.48. The stock has a 50-day moving average of $22.74 and a 200-day moving average of $24.09. The company has a market cap of $853.3 million and a P/E ratio of 44.89.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.41. The company had revenue of $53.90 million for the quarter, compared to the consensus estimate of $57.30 million. During the same quarter last year, the company posted ($0.22) earnings per share. Emergent Biosolutions’s revenue was up 25.1% compared to the same quarter last year. On average, analysts predict that Emergent Biosolutions will post $1.16 earnings per share for the current fiscal year.
Emergent BioSolutions Inc is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.